Literature DB >> 15023321

[How suitable is thromboembolism prophylaxis for patients with chronic auricular fibrillation at 3 primary care centers].

I Romera Fernández1, R de Dios del Valle, A García de Francisco, Y González Rubio, C Lenza Alonso, M A Salinero Fort.   

Abstract

OBJECTIVE: To find just how suitable thromboembolism prophylaxis (TEP) is in a group of patients with chronic auricular fibrillation belonging to the primary care environment.
DESIGN: Cross-sectional and descriptive multi-centre study.
SETTING: The study was performed at 3 urban primary care centres in Madrid. PARTICIPANTS: All the patients recorded up to April 2001 with the diagnosis of chronic auricular fibrillation (n=274) were included. Patients with no clinical history or who had a valve prosthesis were excluded. MAIN MEASUREMENTS: Demographic variables, existence of factors of risk of embolism, presence of counter-indications for oral anti-coagulants, and the kind of thromboembolic prophylaxis taken were collected.
RESULTS: A total of 274 patients were evaluated. Average age was 75 (SD, 9) and 52% were women. 82% of patients had at least one factor of risk of thromboembolism. The most commonly used kind of TEP was oral anti-coagulants. 45% of patients did not receive suitable TEP. 13.5% of patients at risk of embolism and who had no kind of TEP were found.
CONCLUSIONS: There is a high percentage of patients with chronic auricular fibrillation and a high risk of embolism, who do not receive adequate TEP, in the absence of counter-indications to taking oral anticoagulants. There is great scope for improvement, which is within professionals' possibilities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023321      PMCID: PMC7668721          DOI: 10.1016/s0212-6567(04)79392-0

Source DB:  PubMed          Journal:  Aten Primaria        ISSN: 0212-6567            Impact factor:   1.137


  14 in total

Review 1.  [Practice guidelines of the Spanish Society of Cardiology. Recommendations for the use of antithrombotic treatment in cardiology].

Authors:  M Heras; A Fernández Ortiz; J A Gómez Guindal; J A Iriarte; R M Lidón; F Pérez Gómez; I Roldán
Journal:  Rev Esp Cardiol       Date:  1999-10       Impact factor: 4.753

2.  The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation.

Authors:  Daniel E Singer; Robert A Hughes; Daryl R Gress; Mary A Sheehan; Lynn B Oertel; Sue Ward Maraventano; Dyan Ryan Blewett; Bernard Rosner; J Philip Kistler
Journal:  N Engl J Med       Date:  1990-11-29       Impact factor: 91.245

Review 3.  Antithrombotic therapy in atrial fibrillation.

Authors:  A Laupacis; G Albers; J Dalen; M I Dunn; A K Jacobson; D E Singer
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

4.  Use of antithrombotic measures for stroke prevention in atrial fibrillation.

Authors:  I Perez; A Melbourn; L Kalra
Journal:  Heart       Date:  1999-11       Impact factor: 5.994

5.  Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals.

Authors:  G W Albers; J M Yim; K M Belew; N Bittar; C R Hattemer; B G Phillips; S Kemp; E A Hall; D J Morton; P H Vlasses
Journal:  Arch Intern Med       Date:  1996-11-11

6.  Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study.

Authors:  P A Wolf; T R Dawber; H E Thomas; W B Kannel
Journal:  Neurology       Date:  1978-10       Impact factor: 9.910

7.  Canadian Atrial Fibrillation Anticoagulation (CAFA) Study.

Authors:  S J Connolly; A Laupacis; M Gent; R S Roberts; J A Cairns; C Joyner
Journal:  J Am Coll Cardiol       Date:  1991-08       Impact factor: 24.094

8.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Authors:  P A Wolf; R D Abbott; W B Kannel
Journal:  Stroke       Date:  1991-08       Impact factor: 7.914

9.  Stroke Prevention in Atrial Fibrillation Study. Final results.

Authors: 
Journal:  Circulation       Date:  1991-08       Impact factor: 29.690

10.  Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.

Authors: 
Journal:  Arch Intern Med       Date:  1994-07-11
View more
  1 in total

1.  [The management of atrial fibrillation and characteristics of its current care in outpatients. AFABE observational study].

Authors:  Emmanuel Giménez-García; Josep Lluís Clua-Espuny; Ramón Bosch-Príncep; Carlos López-Pablo; Iñigo Lechuga-Durán; Miquel Gallofré-López; Anna Panisello-Tafalla; Jorgina Lucas-Noll; Maria Lluisa Queralt-Tomas
Journal:  Aten Primaria       Date:  2013-09-14       Impact factor: 1.137

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.